Results 1 to 10 of about 60,343,578 (236)

Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis

Cells, 2022
Immune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment for metastatic triple-negative breast cancer (TNBC) patients. However, results of phase II and III clinical trials assessing ICIs plus chemotherapy as neoadjuvant ...
Alessandro Rizzo, Antonio Cusmai, Raffaella Massafra, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Lucia Rinaldi, Silvana Acquafredda, Gennaro Gadaleta-Caldarola, Donato Oreste, Alfredo Zito, Francesco Giotta, Vito Lorusso, Gennaro Palmiotti   +13 more
doaj   +1 more source

Development and clinical advancement of small molecules for ex vivo expansion of hematopoietic stem cell

Acta Pharmaceutica Sinica B, 2022
Hematopoietic stem cell (HSC) transplantation is the only curative therapy for many diseases. HSCs from umbilical cord blood (UCB) source have many advantages over from bone marrow.
Jiaxing Li, Xiao Wang, Jiayu Ding, Yasheng Zhu, Wenjian Min, Wenbing Kuang, Kai Yuan, Chengliang Sun, Peng Yang   +8 more
doaj   +1 more source

Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial

Frontiers in Oncology, 2020
Introduction: Approximately 80% of non-small cell lung cancer (NSCLC) patients with bone metastases have cancer induced bone pain (CIBP).Methods: The NVALT-9 was an open-label, single arm, phase II, multicenter study.
Anita J. W. M. Brouns, Anita J. W. M. Brouns, Lizza E. L. Hendriks, Vincent van der Noort, Ben E. E. M van de Borne, Franz M. N. H. Schramel, Harry J. M. Groen, Bonne Biesma, Hans J. M. Smit, Anne-Marie C. Dingemans, Anne-Marie C. Dingemans   +10 more
doaj   +1 more source

Gene therapy for diabetic peripheral neuropathy: A randomized, placebo‐controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor

Clinical and Translational Science, 2021
VM202 is a plasmid DNA encoding two isoforms of hepatocyte growth factor (HGF). A previous phase II study in subjects with painful diabetic peripheral neuropathy (DPN) showed significant reductions in pain. A phase III study was conducted to evaluate the
John A. Kessler, Aziz Shaibani, Christine N. Sang, Mark Christiansen, David Kudrow, Aaron Vinik, Nari Shin, the VM202 study group   +7 more
doaj   +1 more source

Sharing results with participants (and community) in malaria related research: Perspectives and experience from researchers.

PLOS Global Public Health, 2023
Results-sharing with participants or their communities after the completion of research is an essential element of ethical research. The main objective of this study was to identify and document current practice of trial result dissemination, to explore ...
Sophie Weston, Bipin Adhkari, Kamala Thriemer   +2 more
doaj   +1 more source

Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-Analysis

Frontiers in Oncology, 2020
Background: Several phase-II trials have been designed to evaluate tyrosine kinase inhibitors (TKIs), in particular, pazopanib in neuroendocrine neoplasia (NEN), but its efficacy has not yet been demonstrated in a randomised-controlled Phase III trial. A
Alberto Bongiovanni, Chiara Liverani, Federica Recine, Valentina Fausti, Laura Mercatali, Alessandro Vagheggini, Chiara Spadazzi, Giacomo Miserocchi, Claudia Cocchi, Giandomenico Di Menna, Alessandro De Vita, Stefano Severi, Silvia Nicolini, Toni Ibrahim   +13 more
doaj   +1 more source

A target‐mediated drug disposition population pharmacokinetic model of GC1118, a novel anti‐EGFR antibody, in patients with solid tumors

Clinical and Translational Science, 2021
GC1118 is a monoclonal antibody for epidermal growth factor receptor (EGFR) that is currently under clinical development to treat patients with solid tumors.
Tae Kyu Chung, Hyun A. Lee, Sang‐In Park, Do‐Youn Oh, Keun‐Wook Lee, Jin Won Kim, Jee Hyun Kim, Ahmi Woo, Su Jin Lee, Yung‐Jue Bang, Howard Lee   +10 more
doaj   +1 more source

Optimising recruitment to a late-phase tuberculosis clinical trial: a qualitative study exploring patient and practitioner experiences in Uzbekistan

Trials, 2021
Background Addressing the global burden of multidrug-resistant tuberculosis (MDR-TB) requires identification of shorter, less toxic treatment regimens. Médecins Sans Frontières (MSF) is currently conducting a phase II/III randomised controlled clinical ...
Alexandra Wharton-Smith, Shona Horter, Emma Douch, Nell Gray, Nicola James, Bern-Thomas Nyang’wa, Jatinder Singh, Parpieva Nargiza Nusratovna, Zinaida Tigay, Emil Kazounis, Gulayim Allanazarova, Beverley Stringer   +11 more
doaj   +1 more source

Post-COVID condition or “long COVID”, return-to work, and occupational health research

Scandinavian Journal of Work, Environment & Health, 2023
Since the beginning of the COVID-19 pandemic, there has been a growing literature on COVID and work (1). Major editorials (2–4) and reports from international associations and agencies (5–8) have highlighted the importance of ...
Alexis Descatha, Bradley A Evanoff, Marc Fadel   +2 more
doaj   +1 more source

Current evidence linking polyunsaturated fatty acids (PUFAs) with cancer risk and progression

Frontiers in Oncology, 2013
There is increasing evidence that polyunsaturated fatty acids (PUFAs) play a role in cancer risk and progression. The n-3 family of PUFAs includes alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) while the n-6 family
Maria eAzrad, Chelsea Elizabeth Turgeon, Wendy eDemark-Wahnefried   +2 more
doaj   +1 more source